The FDA's Infant COVID Vax Fraud

The FDA's emergency use authorization of Pfizer's COVID-19 vaccine for infants and toddlers earlier this month was based on brazen scientific fraud.

That will be the subject of my next major article, currently still being written. In the meantime, I'm doing a series of newsletters briefly summarizing key points about how the FDA perpetrated this fraud.

In case you missed my two earlier emails in this series, you can read Part I here and read Part II here.

As I indicated in yesterday's newsletter, today I'll be going over how the FDA lied about the risk factors for child hospitalization due to COVID-19.

Everyone knows that severe COVID-19 and death is associated with certain factors that increase the risk. Age is one important factor, and we've already gone over how extraordinarily low the infection fatality rate is for children: statistically zero.

Severe disease is also associated with numerous underlying medical conditions.

The risk posed by COVID-19 is not the same for every child. Certain children are at higher risk than others. As already discussed, the risk to children is extraordinarily low when considering the total population, including all children with underlying medical conditions placing them at higher risk.

Nevertheless, the FDA attempted to justify its position that the benefits of vaccination outweigh the risks for all children and downplayed the even lower risk to healthy children by claiming that "a majority of children hospitalized for COVID‑19 have no underlying medical conditions."

However, that claim is false.

To support that false claim, the FDA in its decision memorandum cites CDC data to state, "Of children 6 months to 4 years of age with COVID‑19 associated hospitalization, 49% had one or more underlying health conditions."

But that is also false.

First, the dataset referenced does not stratify the data by the age group of six months to four years. Rather, it includes children from birth to four years old, and infants too young to be vaccinated under the FDA's revised emergency use authorization contribute disproportionately to the hospitalization rate among children.

The FDA thus fraudulently exaggerates the risk of hospitalization posed to children aged six months to four years.

Second, the data are not limited to hospitalizations because of COVID-19 but are for "COVID-19-associated" hospitalizations, which includes children who incidentally tested positive for SARS-CoV-2 but were at the hospital for other reasons.

According to one study last fall, 40% of "COVID-19-associated" hospitalizations represent children who were hospitalized for other reasons and incidentally tested positive.

The FDA thus fraudulently exaggerates the risk to children of being hospitalized because of COVID-19.

Third, the data do not show that most children who were hospitalized while testing positive had no other medical conditions placing them at higher risk of severe COVID-19.

On the contrary, only 45 percent of children aged zero to four years are listed under the category of "No known condition". The rest had one or more other underlying medical conditions, including obesity, neurologic disease, asthma, chronic lung disease, gastrointestinal or liver disease, cardiovascular disease, metabolic disease, immune suppression, autoimmune disease, renal disease, or hypertension.

The FDA's claim is also contrasted by the same UK study I mentioned in Part II, which found that children with underlying medical conditions had two to three times the risk of dying from COVID-19, with 75% of child COVID-19 deaths occurring in children with underlying medical conditions.

Of course, the risk of severe disease and death has only grown smaller over time as the proportion of immunologically naïve children has decreased and the virus has mutated to become less virulent, generally cause milder symptoms compared to earlier variants.

Finally, even if the information about the risk to children of hospitalization due to COVID‑19 presented by the FDA were correct, the FDA failed to produce any data to support its assumption that vaccination would reduce that risk among children six months to four years of age.

This is indicative of how the FDA’s decision to authorize the vaccine for infants and toddlers was based on faith and fraud, not scientific evidence.

In my next newsletter, I'll go over how the FDA similarly exaggerates the risk of "Long COVID" in children.